minjuvi
incyte biosciences distribution b.v. - tafasitamab - lymphoma, large b-cell, diffuse - antineoplastiska medel - minjuvi is indicated in combination with lenalidomide followed by minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) who are not eligible for autologous stem cell transplant (asct).
lunsumio
roche registration gmbh - mosunetuzumab - lymfom, follikel - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.
vyvgart
argenx - efgartigimod alfa - myasthenia gravis - immunsuppressiva - vyvgart is indicated as an add on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti acetylcholine receptor (achr) antibody positive.
ebvallo
pierre fabre medicament - tabelecleucel - lymphoproliferative disorders - ebvallo is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory epstein-barr virus positive post-transplant lymphoproliferative disease (ebv+ ptld) who have received at least one prior therapy. for solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.
columvi
roche registration gmbh - glofitamab - lymphoma, large b-cell, diffuse - antineoplastiska medel - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.
inaqovi
otsuka pharmaceutical netherlands b.v. - cedazuridine, decitabine - leukemi, myeloid - antineoplastiska medel - inaqovi is indicated as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for standard induction chemotherapy.
tepkinly
abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - antineoplastiska medel - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.
fludeoxyglucose (18f) karolinska 450-11250 mbq/ml injektionsvätska, lösning
karolinska university hospital - fludeoxiglukos(f-18) - injektionsvätska, lösning - 450-11250 mbq/ml - fludeoxiglukos(f-18) 450 - 11250 mbq aktiv substans
lioresal 0,5 mg/ml injektions-/infusionsvätska, lösning
novartis sverige ab - baklofen - injektions-/infusionsvätska, lösning - 0,5 mg/ml - baklofen 0,5 mg aktiv substans - baklofen
lioresal 0,5 mg/ml injektions-/infusionsvätska, lösning
orifarm ab - baklofen - injektions-/infusionsvätska, lösning - 0,5 mg/ml - baklofen 0,5 mg aktiv substans - baklofen